General Information
Drug ID
DR00148
Drug Name
Digoxin
Synonyms
(3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 12beta-Hydroxydigitoxin; 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}; Digitek (TN); Digoxin (JP15/USP); Lanoxicaps (TN); Lanoxin (TN)
Drug Type
Small molecular drug
Indication Arrhythmias [ICD11: BC60-BC9Z] Approved [1]
Heart failure [ICD11: BD1Z] Approved [1]
Therapeutic Class
Antiarrhythmic Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=2724385"></iframe>
3D MOL 2D MOL
Formula
C41H64O14
Canonical SMILES
CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O
InChI
InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1
InChIKey
LTMHDMANZUZIPE-PUGKRICDSA-N
CAS Number
CAS 20830-75-5
Pharmaceutical Properties Molecular Weight 780.949 Topological Polar Surface Area 203
Heavy Atom Count 55 Rotatable Bond Count 7
Hydrogen Bond Donor Count 6 Hydrogen Bond Acceptor Count 14
XLogP
1.3
PubChem CID
2724385
PubChem SID
10321270 , 103707689 , 103913751 , 111366106 , 11466465 , 11467585 , 11486129 , 11533002 , 117393920 , 121363091 , 14840467 , 16531631 , 17389540 , 24893992 , 24894045 , 25664046 , 26752810 , 29204039 , 30082596 , 3139699 , 46508524 , 47277036 , 47350829 , 47500941 , 47871144 , 48415894 , 48425070 , 48493824 , 49698492 , 49718191 , 50105460 , 50105461 , 56313674 , 56422204 , 57287890 , 57409429 , 57654114 , 7847364 , 79412392 , 7979083 , 85788562 , 87568294 , 8787891 , 90481132 , 9171 , 92125420 , 92298240 , 92729949 , 93167166 , 99431517
ChEBI ID
ChEBI:4551
TTD Drug ID
D02OZE
DT(s) Transporting This Drug MDR3 Transporter Info Multidrug resistance protein 3 Substrate [2]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [3]
OATP2B1 Transporter Info Organic anion transporting polypeptide 2B1 Substrate [4]
OATP4C1 Transporter Info Organic anion transporting polypeptide 4C1 Substrate [5]
OSTalpha Transporter Info Organic solute transporter subunit alpha Substrate [6]
OSTbeta Transporter Info Organic solute transporter subunit beta Substrate [6]
OSTbeta Transporter Info Organic solute transporter subunit beta Substrate [6]
P-GP Transporter Info P-glycoprotein 1 Substrate [7]
Drug-Transporter Activity Data
Drug-Transporter Activity Data OATP4C1 Transporter Info Km = 7.8 microM Madin-Darby canine kidney (MDCK) cells-OATP4C1 [5]
P-GP Transporter Info Km = 25.9 microM High five cells-MDR1 [8]
P-GP Transporter Info Km = 73 microM Human enterocyte-like 2 cells (Caco-2)-MDR1 [9]
P-GP Transporter Info Km = 177 microM Human enterocyte-like 2 cells (Caco-2)-MDR1 [10]
P-GP Transporter Info Km = 181 microM Spodoptera frugiperda (Sf9) cells-MDR1 [11]
References
1 Digoxin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
3 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
4 Drug Interactions in Infectious Diseases.
5 Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74.
6 Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
7 MDR1 function is sensitive to the phosphorylation state of myosin regulatory light chain. Biochem Biophys Res Commun. 2010 Jul 16;398(1):7-12.
8 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
9 Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.
10 Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
11 Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.